Combined Hormonal Contraception
Core concept: Estrogen-progestin pills, patches, and vaginal rings prevent pregnancy primarily by suppressing ovulation.
Key clinical distinction: Appropriate estrogen eligibility is more important than choosing among pill brands.
Prescribing priority: Assess pregnancy possibility, blood pressure, thromboembolic and vascular risk, migraine phenotype, smoking, postpartum status, and interacting medications before prescribing (Vernon, 2026).
Selecting the method
Combined oral contraceptives (COCs) contain an estrogen (usually ethinyl estradiol, with newer estradiol or estetrol products) and a progestin. Monophasic products use constant active-pill strengths; multiphasic products change strength during a cycle. Extended or continuous schedules reduce scheduled bleeding. Patches and vaginal rings offer non-daily dosing but still expose the patient to estrogen-related risks. Preferences regarding bleeding, adherence, cost, acne, dysmenorrhea, and access affect selection (Vernon, 2026).
Clinical eligibility and baseline assessment
Measure blood pressure and use the current U.S. Medical Eligibility Criteria (MEC) for the precise condition and formulation. Combined hormonal contraception is generally inappropriate with migraine with aura, prior venous thromboembolism with significant recurrence risk, current breast cancer, severe or uncontrolled hypertension, major vascular disease, and smoking at age 35 or older when risk meets MEC category 3 or 4. Early postpartum status and breastfeeding require a time-specific assessment. A pelvic examination and routine laboratory panel are not prerequisites for most patients initiating COCs. Review the possibility of pregnancy rather than requiring a test indiscriminately (Vernon, 2026).
Selecting and initiating treatment
A common low-dose COC supplies ethinyl estradiol 20–35 mcg daily with an appropriate progestin; selection is product-specific. If a patient is reasonably certain not pregnant, CHCs may usually be started without waiting for the next menstrual period. Starting more than five days after menstrual bleeding begins generally requires seven days of backup contraception. Follow product-specific instructions for patches and rings, which differ from oral formulations. CHCs do not prevent sexually transmitted infections; recommend barrier protection when exposure is possible (Vernon, 2026).
Missed doses, adverse effects, and interactions
CDC 2024 U.S. Selected Practice Recommendations distinguish a single late/missed active combined oral contraceptive (COC) pill (less than 48 hours since due) from two or more missed active pills (48 hours or longer). With one late/missed pill, take it promptly, continue the pack, and no backup is ordinarily needed. After two or more missed active pills, take only the most recent missed pill, continue the pack, and use barrier protection or abstain until seven consecutive hormonal pills have been taken. If this occurs in the final active-pill week, omit the hormone-free interval and immediately start the next pack. Consider emergency contraception when missed pills occur in week one with unprotected intercourse in the preceding five days; use separate guidance for ulipristal because progestins can reduce its effectiveness. CDC publishes distinct 48-hour and seven-day algorithms for missed patches and etonogestrel/ethinyl estradiol rings; these should not be applied to all ring brands indiscriminately (CDC, 2024, Combined Hormonal Contraceptives).
Spotting, nausea, and breast tenderness may improve with continued use. Assess new severe headache, focal neurologic symptoms, chest pain, dyspnea, or unilateral leg swelling urgently rather than labeling them routine side effects. Enzyme-inducing anticonvulsants, rifampin-like antibiotics, and selected antiretrovirals can reduce contraceptive effectiveness; contraceptives also interact bidirectionally with lamotrigine. Drospirenone-containing products warrant attention to potassium-related interactions in susceptible patients (Vernon, 2026).
Choosing among estrogen and progestin formulations
The estrogen dose and progestin type are distinct decisions. Common combination products contain ethinyl estradiol (EE) in strengths ranging from very low doses to 35 mcg, while selected alternatives use estradiol or estetrol. Levonorgestrel and norethindrone are established progestins; norgestimate and desogestrel have comparatively less androgenic activity; drospirenone has antiandrogenic and antimineralocorticoid effects. These pharmacologic differences can influence acne, bleeding, and drug interactions, but none overcomes an estrogen contraindication. Thromboembolic risk assessment should follow the patient’s overall vascular and medical eligibility profile rather than assuming that progestin choice overrides estrogen-associated risk (Vernon, 2026).
Choosing the delivery route and bleeding schedule
Weekly patches and vaginal rings can help patients who have difficulty remembering daily tablets, but product-specific instructions matter. NuvaRing labeling states that expulsion for more than three continuous hours can require backup and a week-dependent replacement plan; CDC selected practice recommendations use an evidence-based late-use algorithm that is not identical to every label. The Annovera system is reused for thirteen 28-day cycles (21 days in, 7 days out); more than two continuous or cumulative hours out during a 21-day use period requires backup until seven consecutive days in place. Twirla, Xulane, and Zafemy are contraindicated at BMI 30 kg/m² or above. Twirla may have reduced effectiveness at BMI 25–29.9 kg/m²; Xulane and Zafemy warn about reduced efficacy at weight 90 kg or above. Confirm the chosen product’s eligibility, starting instructions, and missed-use plan before prescribing. When bleeding persists, reassess adherence, pregnancy, infection, and interactions before changing formulation (CDC, 2024; Organon, 2025; Mayne Pharma, 2026; Exeltis USA, 2026; AvKARE, 2026; Vernon, 2026).
Comparison of specific combined contraceptive choices
For a patient who is eligible for estrogen and can reliably take a daily pill, a monophasic ethinyl estradiol (EE) 20 mcg/levonorgestrel 0.1 mg product is an established low-dose option. EE 20 mcg/drospirenone 3 mg may be considered when acne or cycle-related symptoms are important, but drospirenone-related potassium concerns and patient-specific vascular risks still require review. EE 30 mcg/levonorgestrel 0.15 mg provides an alternative estrogen strength when persistent unscheduled bleeding is problematic after adherence, pregnancy, infection, and interactions are assessed. A product containing only 10 mcg EE may worsen breakthrough bleeding despite reducing some estrogen-related symptoms. These examples are alternatives to compare, not interchangeable prescriptions: verify pack structure and product-specific labeling (Vernon, 2026).
Manage bleeding and nonresponse without reflexive escalation
At approximately three months, determine whether spotting is improving and whether missed tablets, new enzyme-inducing drugs, pregnancy possibility, or cervicitis explain it. If correct use and safety are established but bleeding remains unacceptable, compare a monophasic formulation with a different estrogen dose, an extended schedule, or a different delivery route. Never increase estrogen to overcome a category 4 medical contraindication. For severe new headaches, VTE symptoms, or major blood-pressure changes, stop the routine adjustment pathway and evaluate promptly (Vernon, 2026).
Representative combined formulations (not a substitution chart)
| Example from Chapter 49 | Daily hormones or delivery | Why it may be chosen | Clinical limitation |
|---|---|---|---|
| EE/levonorgestrel | 20 mcg EE + 0.1 mg LNG | Familiar lower-EE monophasic option | Adherence and estrogen eligibility |
| EE/drospirenone | 20 mcg EE + 3 mg drospirenone | Acne and hormone-free interval priorities | Potassium/interactions; estrogen risks |
| EE/levonorgestrel | 30 mcg EE + 0.15 mg LNG | Compare when cycle control is inadequate | Different estrogen exposure; individual risk |
| EE/norethindrone acetate | 20 mcg EE + 1 mg norethindrone acetate | Alternative progestin choice | Product-specific active/placebo schedule |
| Patch or vaginal ring | Weekly patch or 3-week ring cycle | Avoid daily tablets | Patch BMI restrictions and individual labeling |
Clinical application
A 24-year-old with bothersome acne, predictable menses, BP 112/68, no migraine aura, and no thrombosis history requests a pill. She previously had persistent spotting on EE 20 mcg/levonorgestrel 0.1 mg despite documented adherence. Compare another low-dose preparation containing drospirenone with an EE 30 mcg/levonorgestrel product: the former may offer an antiandrogenic progestin but needs a potassium/interactions review; the latter may improve cycle control with greater estrogen exposure. Confirm pregnancy and STI risks and shared priorities first, choose one labeled schedule, and plan a three-month symptom/adherence reassessment (Vernon, 2026).
High-yield distinctions
Lower estrogen dose does not eliminate estrogen-associated vascular contraindications. Bleeding-pattern convenience is secondary to safety. Breakthrough bleeding alone does not establish contraceptive failure. Reassess blood pressure, new comorbidities, adherence, and interacting drugs at follow-up.
Related YourDNP Resources
Pharmacology learning hub · Progestin-only contraception and long-acting reversible methods · Emergency contraception · Chlamydia and genital warts
Content last reviewed:
References
AvKARE. (2026). Zafemy (norelgestromin/ethinyl estradiol) transdermal system: U.S. prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbbd12dd-c538-2869-e053-6294a90a1a38
Centers for Disease Control and Prevention. (2024, November 19). Combined hormonal contraceptives: U.S. selected practice recommendations. https://www.cdc.gov/contraception/hcp/usspr/combined-hormonal-contraceptives.html
Exeltis USA, Inc. (2026). Twirla (levonorgestrel/ethinyl estradiol) transdermal system: U.S. prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcaf8db0-1750-425d-b008-255b5e7a9cc6
Mayne Pharma. (2026). Annovera (segesterone acetate/ethinyl estradiol) vaginal system: U.S. prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb18194f-2021-41fa-8bdf-31e0c0eb646b
Organon LLC. (2025). NuvaRing (etonogestrel/ethinyl estradiol) vaginal ring: U.S. prescribing information. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55eb60e3-6f4d-40a3-8ee6-e7fd2d0c7d97
Reproductive Health National Training Center. (2024). Birth control methods chart [Patient education chart].
Vernon, V. P. (2026). Contraception. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 49). McGraw Hill.